Kyverna Therapeutics is a biotech startup that operates in the healthcare sector, specifically in the field of autoimmune disease treatment. The company is focused on developing innovative cell therapies that can potentially cure autoimmune diseases. Their primary clients are patients suffering from autoimmune diseases, a market that is continually growing due to the increasing prevalence of these conditions.

Kyverna's business model revolves around the use of synthetic biology, immunology, and cell engineering to create a new class of T cell therapies. These therapies are designed to target and modulate the underlying causes of autoimmunity. Unlike traditional treatments that require chronic dosing, Kyverna's cell therapy aims to control the disease optimally and long-lastingly through a single infusion. This approach could potentially revolutionize the treatment of autoimmune diseases, providing a more effective and convenient solution for patients.

The company also seeks to expand its technology and capabilities through in-licensing and collaboration opportunities. This strategy allows Kyverna to stay at the forefront of cell therapy innovation and ensure its therapies are as effective and advanced as possible.

In terms of revenue, Kyverna makes money by developing and selling its cell therapies to patients and healthcare providers. The company's potential for growth and profitability is significant, given the high demand for effective treatments for autoimmune diseases.

Keywords: Biotech, Healthcare, Autoimmune Diseases, Cell Therapy, T Cell Therapies, Synthetic Biology, Immunology, Cell Engineering, In-Licensing, Collaboration.